Baseline Predictors of LDL-Cholesterol and Systolic Blood Pressure Goal Attainment After One-Year in the ISCHEMIA Trial
Embargoed until 4 a.m. CT / 5 a.m. ET, Wednesday, Nov. 13, 2019
( NewMediaWire ) - November 13, 2019 - DALLAS - In this analysis of 3,984 participants from ISCHEMIA (78% of 5179 randomized) with available data, predictors of reaching one-year goals are reported for low-density lipoprotein cholesterol (LDL-C) and systolic blood pressure (SBP). This paper was led by Jonathan Newman, M.D., M.P.H., from the New York University School of Medicine, and the ISCHEMIA trial investigators and is published today in Circulation: Cardiovascular Quality and Outcomes, an online-only, peer-reviewed journal of the American Heart Association dedicated to furthering the mission of promoting safe, effective, efficient, equitable, timely and patient-centered care.
It is known that risk factor control reduces events and improves survival for patients with stable ischemic heart disease (SIHD), however, it is often difficult to achieve. The ISCHEMIA authors found that levels of risk factor control at baseline, along with medication use and other demographic factors, predicted goal attainment at one year. Goal achievement was not analyzed by treatment group assignment, and final goal attainment was not reported.
The findings from this study of interim data from ISCHEMIA may inform researchers and clinicians regarding which patients are more or less likely to achieve risk factor control after one year using similar medical therapies and sets the stage for the presentation of ISCHEMIA results in the Late-Breaking Science 2 sessions at American Heart Association’s Scientific Sessions 2019.
In an accompanying editorial, also published today in Circulation: Cardiovascular Quality and Outcomes, Rasha Al-Lamee, M.A. (Oxford), M.B.B.S., M.R.C.P.; Christopher Rajkumar, M.B.B.S., B.Sc., M.R.C.P.; and Michael Foley, Ph.D., from the Imperial College of London put these important findings from ISCHEMIA into perspective and discuss the critical role of baseline medical therapy in understanding trials of coronary revascularization.
After 5 a.m. ET, Nov. 13, view the Newman manuscript online.
After 5 a.m. ET, Nov. 13, view the Al-Lamee editorial online.
Follow AHA/ASA news on Twitter @HeartNews
Statements and conclusions of study authors published in American Heart Association scientific journals are solely those of the study authors and do not necessarily reflect the Association’s policy or position. The Association makes no representation or guarantee as to their accuracy or reliability. The Association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific Association programs and events. The Association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations and health insurance providers are available at https://www.heart.org/en/about-us/aha-financial-information.
About the American Heart Association
The American Heart Association is a relentless force for a world of longer, healthier lives. We are dedicated to ensuring equitable health in all communities. Through collaboration with numerous organizations, and powered by millions of volunteers, we fund innovative research, advocate for the public’s health and share lifesaving resources. The Dallas-based organization has been a leading source of health information for nearly a century. Connect with us on heart.org, Facebook, Twitter or by calling 1-800-AHA-USA1.
For Media Inquiries and AHA/ASA Expert Perspective: 214-706-1173
Michelle Kirkwood: 703-457-7838; email@example.com
Public Inquiries: 1-800-AHA-USA1 (242-8721)